| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study
|
Zhou, Na
|
|
|
160 |
C |
p. 111-117
|
artikel
|
| 2 |
Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review
|
Tota, Vito
|
|
|
160 |
C |
p. 59-65
|
artikel
|
| 3 |
Augmentation method for convolutional neural network that improves prediction performance in the task of classifying primary lung cancer and lung metastasis using CT images
|
Usuzaki, Takuma
|
|
|
160 |
C |
p. 175-178
|
artikel
|
| 4 |
Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer
|
Cheung, Carol C.
|
|
|
160 |
C |
p. 127-135
|
artikel
|
| 5 |
Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study
|
Bhalla, Sheena
|
|
|
160 |
C |
p. 78-83
|
artikel
|
| 6 |
Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma
|
Shen, Mingjing
|
|
|
160 |
C |
p. 84-91
|
artikel
|
| 7 |
Contents
|
|
|
|
160 |
C |
p. v-vi
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
160 |
C |
p. iii
|
artikel
|
| 9 |
eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer
|
Buma, Alessandra I.G.
|
|
|
160 |
C |
p. 36-43
|
artikel
|
| 10 |
Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance
|
Liu, Di
|
|
|
160 |
C |
p. 32-35
|
artikel
|
| 11 |
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
|
Nagasaka, Misako
|
|
|
160 |
C |
p. 92-98
|
artikel
|
| 12 |
Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy
|
Tian, Panwen
|
|
|
160 |
C |
p. 50-58
|
artikel
|
| 13 |
Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencing
|
Wang, Fang
|
|
|
160 |
C |
p. 1-7
|
artikel
|
| 14 |
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
|
Lindsay, Colin R.
|
|
|
160 |
C |
p. 152-165
|
artikel
|
| 15 |
Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway
|
Vauchier, Charles
|
|
|
160 |
C |
p. 28-31
|
artikel
|
| 16 |
Primary lung carcinoma in children and adolescents – Clinical characteristics and outcome of 12 cases from the German registry for rare paediatric tumours (STEP)
|
Voggel, Sarah
|
|
|
160 |
C |
p. 66-72
|
artikel
|
| 17 |
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)
|
Tufman, Amanda
|
|
|
160 |
C |
p. 17-27
|
artikel
|
| 18 |
Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma
|
Aokage, Keiju
|
|
|
160 |
C |
p. 8-16
|
artikel
|
| 19 |
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
|
Steendam, Christi M.J.
|
|
|
160 |
C |
p. 44-49
|
artikel
|
| 20 |
Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis
|
Safavi, Amir H.
|
|
|
160 |
C |
p. 179-186
|
artikel
|
| 21 |
Stereotactic radiotherapy for early-stage (T1-2N0) small cell lung cancer: Where are we now and where are we going?
|
Verma, Vivek
|
|
|
160 |
C |
p. 187-189
|
artikel
|
| 22 |
The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC
|
Shah, Parth
|
|
|
160 |
C |
p. 118-126
|
artikel
|
| 23 |
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC)
|
Kulasinghe, Arutha
|
|
|
160 |
C |
p. 73-77
|
artikel
|
| 24 |
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
|
Melosky, Barbara
|
|
|
160 |
C |
p. 136-151
|
artikel
|
| 25 |
Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models
|
Mumblat, Helena
|
|
|
160 |
C |
p. 99-110
|
artikel
|
| 26 |
YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes
|
Wang, Xin
|
|
|
160 |
C |
p. 166-174
|
artikel
|
Tijdschrift beschrijving